

SUPPLEMENTARY DATA

Supplementary Table 1. Clinical characteristics of study subjects

	NGT (N=196)	T1D (N=53)	LADA (N=250)	T2D (N=285)
Male (%)	63.77(125/196)	75.47(40/53)	62.00(155/250)	62.81(179/285)
Age (yrs)	42.97±7.29	40.77±9.89	50.50±11.91 ^{***###}	49.56±11.12 ^{***###}
BMI (kg/m ²)	23.98±3.08	21.94±5.19 ^{***}	23.98±3.72 ^{###}	24.52±3.19 ^{###}
Waist circumference (cm)	82.79±8.94	76.33±8.44 ^{**}	84.88±10.54 ^{***###}	87.29±13.50 ^{***###&}
Waist-hip ratio	0.86±0.01	0.84±0.06 [*]	0.89±0.07 ^{***###}	0.91±0.07 ^{***###&}
sBP (mmHg)	113.08±13.01	113.74±19.14	124.16±18.02 ^{***###}	126.69±16.24 ^{***###}
dBp (mmHg)	75.72±9.90	74.26±13.08 [*]	78.66±10.32 ^{***}	79.83±9.75 ^{***}
Triglycerides (mmol/L) [¶]	1.35 (0.99-2.05)	1.14(0.76-2.22)	1.60(1.08-2.41)	1.70(1.26-2.64) ^{***###&}
HDL-ch (mmol/L) [¶]	1.21(1.04-1.43)	1.08(1.00-1.30)	1.20(1.02-1.49)	1.18(0.97-1.48) ^{&}
FPG (mmol/L) [§]	5.05±0.32	10.91±0.86 ^{***}	9.84±3.99 ^{***###}	9.65±4.02 ^{***###}
HbA1c (%)	N/A	8.57±3.37	9.45±2.55	9.13±2.58
Fasting plasma insulin (µU/ml) ^{¶§}	5.66(4.13-9.34)	N/A	7.22(4.07-12.74)	8.52(5.09-12.84) ^{***&}
HOMA-IR ^{¶§}	1.26(0.89-2.10)	N/A	2.89(1.46-5.29) ^{***}	3.16(1.98-5.65) ^{***&}
FCP (nmol/L) [¶]	N/A	0.17(0.08-0.27)	0.72(0.32-1.47) ^{###}	1.17(0.63-2.15) ^{###&&}
Metabolic syndrome (%)	44.38% (87/196)	10.81%(4/37) ^{**}	62.4%(156/250) ^{***###}	69.47(198/285) ^{***###}
Insulin treatment at diagnosis(%) [†]	N/A	94.33%(50/53)	34.0% (85/250) ^{###}	22.81%(65/285) ^{###&&}
Hs-CRP(mg/L) ^{¶¶}	0.84(0.39-1.64)	0.54(0.30-1.15) [*]	1.59(0.74-2.96) ^{***###}	1.78(0.82-3.21) ^{***###}
Adiponectin(ug/ml) ^{¶¶}	6.62(4.14-10.46)	6.76(4.38-19.73) [*]	4.98(2.40-10.35) ^{###}	4.50(2.74-7.32) ^{###}
LCN2(ug/L) ^{¶¶}	23.79(17.60-33.98)	39.23(22.14-64.73) ^{**}	39.68(22.85-71.64) ^{***}	46.09(26.15-97.54) ^{***###&}
IL6(pg/ml) ^{¶¶}	1.40(0.99-2.20)	1.72(1.10-3.01) ^{**}	1.80(1.27-3.17) ^{***}	2.27(1.54-4.80) ^{***###&}

Data expressed as Mean ± SEM and compared after Log transformation; Other data expressed by Mean±SD; § Compared after excluding subjects treated by insulin at the sample collection time point; † for LADA and T2D, insulin treatment at diagnosis was less than 1 months then change to oral medicine (follow up at least 6 months to confirm insulin independent); * Compared with NGT P<0.05, ** Compared with NGT P<0.01; *** Compared with NGT P<0.001; # Compared with T1D P<0.05, ## Compared with T1D P<0.01; ### Compared with T1D P<0.001; & Compared with LADA P<0.05, && Compared with LADA P<0.01, &&& Compared with LADA P<0.001. NGT= Normal Glucose Tolerance subjects, T1D= Type 1 diabetes subjects, T2D = Type 2 diabetes subjects, sBP = systolic blood pressure, dBp = diastolic blood pressure

SUPPLEMENTARY DATA

Supplementary Table 2. Adjusted comparisons between LADA, type 1, type 2 diabetes and control groups

Cytokine/ model	LADA vs T1D ()	LADA vs T2D ()	T1D vs T2D()	NGT vs LADA ()	NGT vs T1D ()	NGT vs T2D ()
Hs-CRP						
1	0.328***	0.053	0.356***	0.288***	-0.123	0.335***
2	0.276***	0.060	0.301***	0.249***	-0.129*	0.294***
3	0.241***	0.034	0.256***	0.258***	-0.095	0.271***
Adiponectin						
1	-0.199***	-0.079	-0.300***	-0.139**	0.148*	-0.260***
2	-0.253***	-0.077	-0.355***	-0.163**	0.171**	-0.262***
3	-0.245***	-0.059	-0.361***	-0.172***	0.193**	-0.254***
LCN2						
1	0.075	0.111*	0.148**	0.381***	0.237***	0.462***
2	0.094	0.109*	0.166**	0.399***	0.229***	0.465***
3	0.081	0.106*	0.163**	0.402***	0.224**	0.461***
IL6						
1	0.014	0.173**	0.168*	0.248***	0.207**	0.403***
2	-0.016	0.177**	0.144	0.212***	0.209**	0.397***
3	0.009	0.181***	0.199**	0.212***	0.200**	0.404***

Multiple linear regression models were performed for cytokines. Cytokines were entered into the models as log-transformed variables. Model 1: unadjusted; model 2: age and sex; model 3: age, sex and BMI. *p<0.05; **p<0.01; ***p<0.001. T1D=type 1 diabetes, T2D= type 2 diabetes, NGT=normal glucose tolerance control subjects

SUPPLEMENTARY DATA

Supplementary Table 3. Correlation values for cytokines (for P<0.01 or less) according to clinical, biochemical and immunological parameters and type of diabetes.

	Hs-CRP(mg/L)¶					Adiponectin (ug/ml)¶				
	NGT	T1D	LADA	T2D	Total	NGT	T1D	LADA	T2D	Total
Waist-hip ratio	0.24***				0.21***					-0.16***
sBP (mmHg)					0.09**					-0.13***
dBP (mmHg)					0.10**					-0.13***
TG (mmol/L) ¶					0.12***				-0.18**	-0.14***
HDL-ch (mmol/L) ¶					-0.11**					0.10**
FPG (mmol/L) \$					0.17***					
HbA1c (%)										
FINS (µU/ml) ¶\$				0.21***						
HOMA-IR¶\$					0.22**					-0.23***
HOMA- ¶\$				0.20**	0.18***					
FCP (nmol/L) ¶										
MetS (%)	0.20**			0.18**	0.23***					-0.18***
GADA					-0.15***					0.14**

SUPPLEMENTARY DATA

Hs-CRP(mg/L)¶¶				N/A						-0.10**
Adiponectin(ug/ml)¶¶				-0.10**						N/A
LCN2(ug/L)¶¶			0.27***	0.26***						-0.17***
IL6(pg/ml)¶¶	0.34***	0.33***	0.29***	0.36***						

¶¶ Data compared after Log transformation.

Partial correlations adjusted age, gender and BMI: *** P<0.001, ** P<0.01.

NGT = Normal Glucose Tolerance, T1D = type 1 diabetes, T2D = type 2 diabetes.

sBP = systolic blood pressure, dBP = diastolic blood pressure, TG = triglycerides, FINS = fasting plasma insulin, MetS = metabolic syndrome.